Vivimed Labs Gains 2.91%: 5 Key Factors Driving the Week’s Volatility

09 February 2026: Upper Circuit Triggered on Strong Buying

Vivimed Labs Ltd surged sharply on 09 Feb 2026, hitting its upper circuit limit with a closing price of ₹7.51, a gain of 4.29% from the previous close of ₹7.22. The stock opened at ₹6.91 and traded with high volatility, supported by a robust volume of 3.20 lakh shares. This marked a rebound after five consecutive days of decline, driven by intense buying interest that overwhelmed supply and led to a regulatory freeze on further price appreciation. Despite the positive price action, the stock remained below all key moving averages, and the recent downgrade to a Strong Sell mojo rating underscored persistent fundamental concerns.

10 February 2026: Sharp Reversal to Lower Circuit Amid Heavy Selling

The following day, 10 Feb 2026, Vivimed Labs reversed sharply, hitting the lower circuit limit and closing at ₹7.29, down 3.98% from the previous close. The stock underperformed both its sector and the Sensex, which gained modestly. Heavy selling pressure was evident with a volume of 7.3 lakh shares and a surge in delivery volume by 169.38%, signalling panic selling. The stock’s technical position deteriorated further as it continued trading below all major moving averages, reflecting sustained bearish sentiment despite adequate liquidity.

11 February 2026: Continued Downtrend Hits Lower Circuit Again

On 11 Feb 2026, Vivimed Labs again hit the lower circuit, closing at ₹6.80, a 4.98% decline from the prior close. This brought the stock perilously close to its 52-week low of ₹6.72, just 1.18% above that level. The stock underperformed its sector and the Sensex, which posted small gains. Delivery volumes surged by 137.83%, indicating increased investor offloading. The persistent trading below all key moving averages and the Strong Sell mojo rating reinforced the negative outlook. The circuit breaker halt reflected extreme volatility and unfilled sell orders, highlighting the stock’s fragile position.

12 February 2026: Upper Circuit Rally Amid Sector Weakness

Vivimed Labs rebounded strongly on 12 Feb 2026, hitting the upper circuit limit again with a 4.51% gain to close at ₹7.18. This rally occurred despite the Pharmaceuticals & Drugs sector declining by 0.25% and the Sensex falling 0.36%. The stock’s volume was moderate at just under 2 lakh shares, with delivery volume increasing by 23.65%, signalling renewed investor interest. However, the stock remained below all key moving averages except for a short-term bounce, and its proximity to the 52-week low continued to weigh on sentiment. The surge was likely driven by speculative buying and short-covering rather than fundamental improvement.

13 February 2026: Sustained Buying Pushes Stock to Upper Circuit

On the final trading day of the week, 13 Feb 2026, Vivimed Labs again surged to the upper circuit limit, closing at ₹7.43 with a 3.48% gain. The stock outperformed its sector, which declined by 0.81%, and the Sensex, which fell 0.98%. Volume was moderate at 1.46 lakh shares, though delivery volume dropped sharply by 42.71%, indicating a shift in investor participation dynamics. Technically, the stock’s last traded price rose above its five-day moving average but remained below longer-term averages, reflecting a mixed technical outlook. The Strong Sell mojo rating and micro-cap status continue to signal caution despite the short-term momentum.

Daily Price Performance: Vivimed Labs vs Sensex

Key Takeaways from the Week

Volatility and Circuit Hits: Vivimed Labs experienced extreme price swings, hitting upper circuit limits thrice and lower circuit limits twice within five trading sessions. This reflects a highly volatile trading environment with rapid shifts in investor sentiment.

Outperformance vs Sensex: Despite the volatility, the stock closed the week up 2.91%, outperforming the Sensex which declined 0.54%. This relative strength was driven by short bursts of strong buying interest amid broader market weakness.

Technical Weakness Persists: The stock remained below all major moving averages for most of the week, signalling a continuing downtrend. The brief rallies appear to be technical bounces rather than sustained recoveries.

Strong Sell Mojo Rating: The company’s mojo score of 24.0 and Strong Sell grade reflect deteriorating fundamentals and analyst caution, which likely contributed to the heavy selling pressure and investor anxiety.

Micro-Cap Risks and Liquidity: With a market capitalisation around ₹60 crore, Vivimed Labs is a micro-cap stock prone to volatility and liquidity constraints. Delivery volumes fluctuated sharply, indicating changing investor participation and potential speculative trading.

Conclusion: A Week of Sharp Swings Amid Fundamental Concerns

Vivimed Labs Ltd’s trading week was marked by intense volatility, with multiple upper and lower circuit hits reflecting a battle between speculative buying and panic selling. While the stock managed to close the week with a 2.91% gain, outperforming the Sensex, the underlying technical and fundamental indicators remain weak. The Strong Sell mojo rating and proximity to the 52-week low underscore ongoing challenges. Investors should approach the stock with caution, recognising the risks inherent in its micro-cap status and the potential for continued sharp price fluctuations. Monitoring delivery volumes, sector trends, and any corporate developments will be essential to gauge the sustainability of any future momentum.

Unlock special upgrade rates for a limited period. Start Saving Now →